Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Wave Life Sciences's price to book ratio was 1.5× on Nov 11, 2026, against 10.7× a year earlier. Over the last 5 years it ranged from 1.5× to 31.8×, with a median of 6.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.5× | −20.4 |
| 2025 | Dec 31, 2025 | 21.9× | +8.9 |
| 2024 | Dec 31, 2024 | 13.0× | −0.5 |
| 2022 | Oct 31, 2022 | 13.4× | +8.0 |
| 2021 | Dec 31, 2021 | 5.5× | +1.9 |
| 2020 | Dec 31, 2020 | 3.5× | +1.2 |
| 2019 | Dec 31, 2019 | 2.4× | −9.2 |
| 2018 | Dec 31, 2018 | 11.6× | +5.7 |
| 2017 | Dec 29, 2017 | 5.9× | +1.8 |
| 2016 | Dec 30, 2016 | 4.1× | – |
See a number that looks wrong?